Merus Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>MN</div>
MRUS -- USA Stock  

USD 24.55  1.24  5.32%

While some millenniums are indifferent towards healthcare space, it makes sense to sum up Merus N V. We will check why this entity may not get much respect from retail investors given the current market uncertainty. Is the firm valuation justified? I am going to cover Merus N V perspective on valuation to give you a better outlook on taking a position in it.
Published over a week ago
View all stories for Merus N | View All Stories
Ready to invest in Merus N now and drop it before the next press release?
This firm currently holds 4.27 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest Merus N is not taking enough advantage from borrowing. The company has a current ratio of 4.34, suggesting that it is liquid enough and is able to pay its financial obligations when due. Our advice module complements current analysts and expert consensus on Merus N V. It analyzes the company potential to grow using all fundamental, technical, and market related data available at the time.
We determine the current worth of Merus N V using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Merus N V based exclusively on its fundamental and basic technical indicators. By analyzing Merus N's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Merus N's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Merus N. We calculate exposure to Merus N's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Merus N's related companies.

Merus N V Investment Alerts

Merus investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Merus N V performance across your portfolios.Please check all investment alerts for Merus

Merus N Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Merus value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Merus N competition to find correlations between indicators driving the intrinsic value of Merus.

How Merus utilizes its cash?

To perform a cash flow analysis of Merus N, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Merus N is receiving and how much cash it distributes out in a given period. The Merus N cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Merus N Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Merus N reported last year Net Cash Flow from Operations of (56.74 Million)

Another Deeper Perspective

Merus N V reported the previous year's revenue of 28.72 M. Net Loss for the year was (82.97 M) with loss before overhead, payroll, taxes, and interest of (24.55 M).

Margins Breakdown

Merus profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Merus N itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Merus N profit margins.
EBITDA Margin(2.15)
Gross Margin0.89
Profit Margin(2.2)

Merus N Average Equity is relatively stable at the moment. Merus N Earnings before Tax is decreasing over the last 8 years. The previous year's value of Merus N Earnings before Tax was -53,366,139. Additionally, Merus N Earnings Before Interest Taxes and Depreciation Amortization USD is relatively stable at the moment. Merus N Average Equity is relatively stable at the moment. Merus N Earnings before Tax is decreasing over the last 8 years. Additionally, Merus N Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years. The previous year's value of Merus N Earnings Before Interest Taxes and Depreciation Amortization USD was -52,261,082.

Our perspective of the latest Merus N spike

Semi variance is down to 6.0. It may connote a possible volatility fall. As of the 9th of January, Merus N secures the Risk Adjusted Performance of 0.1446, mean deviation of 2.37, and Downside Deviation of 2.79. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Merus N V, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Merus N, which can be compared to its peers in the industry. Please verify Merus N V variance and potential upside to decide if Merus N V is priced some-what accurately, providing market reflects its recent price of 20.73 per share. Given that Merus N V has jensen alpha of 0.3924, we recommend you to check Merus N's last-minute market performance to make sure the company can sustain itself at a future point.

While some firms under the biotechnology industry are still a bit expensive, Merus N may offer a potential longer-term growth to retail investors. The bottom line, as of the 9th of January 2021, we see that Merus N slowly supersedes the market. The enterprise is fairly valued with very small chance of financial distress within the next 24 months. Our present 30 days buy-or-sell advice on the enterprise is Buy.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Merus N V. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to